An interventional study of GP0112 and Juvéderm Voluma XC in Cheek Wrinkles and Midface Contour Deficiencies, sponsored by Galderma R&D. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Galderma R&D (part of Galderma Group AG) · Not applicable, Interventional, and Treatment
This is a randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies.
Approximately 326 subjects will be randomized (1:1) to either treatment with GP0112 or Juvéderm Voluma XC(also known as Juvéderm Voluma with lidocaine).
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single injection and optional touch-up injection with GP0112
Device: GP0112
Single injection and optional touch-up injection with Juvéderm Voluma XC
Device: Juvéderm Voluma XC
Injectable gel
Injectable gel
Responder rate based on the Blinded Evaluators' live assessment using the Medicis Midface Volume Scale (MMVS).
A responder is defined as a subject with at least 1 grade improvement from baseline on both sides of the face concurrently.
Time frame: At Month 6 after last treatment.
Responder rate based on the Blinded Evaluator's live assessment of the MMVS.
Time frame: At Months 1, 3, 9 and 12 after last treatment.
Change from baseline in subject satisfaction using the FACE-Q Natural Appearance questionnaires Rasch transformed total scores as well as proportion of subjects in each response category for each of the individual questions.
Time frame: At Months 1, 3, 6, 9 and 12 after last treatment.
Change from baseline in subject satisfaction using the FACE-Q Natural Outcome questionnaires Rasch transformed total scores as well as proportion of subjects in each response category for each of the individual questions.
Time frame: At Months 1, 3, 6, 9 and 12 after last treatment.
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.